Business
BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision
BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision.
About this update from Bioregenx, Inc
[{"type":"text","content":"\r\n\r\n \r\n \r\n BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision\r\n \r\n \r\n\r\n\r\nBioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision\r\nCompany Finalizes GlycoCheck® License, Advances DocSun AI Acquisition and SDK Partnerships, and Engages Investment Bank for Planned 2026 Initiatives\r\n\r\n\r\n\r\n\r\n\r\nCHATTANOOGA, Tenn., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BioRegenx, Inc. (“BioRegenx” or the “Company”) (OTC: BRGX), a health-technology company pioneering non-invasive diagnostic and predictive analytics solutions for microvascular and metabolic health, today announced a series of significant corporate, technological, and strategic milestones. Highlights \r\n Engaged a new PCAOB-registered independent auditor following industry-wide SEC actions affecting prior firms.\r\n Finalized intellectual property license for the clinically validated GlycoCheck® vascular diagnostic platform.\r\n Fully integrated DocSun Biomedical Holdings, Inc., adding AI-driven non-contact vital-sign detection and SDK licensing capabilities.\r\n DocSun executed multiple Letters of Intent (LOIs) with recognized technology companies to explore SDK integrations within their platforms.\r\n Executed a letter of engagement with an investment bank to further pursue its planned corporate strategies in 2026.\r\n Corporate Update and Auditor Engagement In 2024, following the SEC’s enforcement actions that shuttered several audit firms —including BF Borges CPA PC, which affected approximately 500 public issuers—BioRegenx engaged a new PCAOB-registered independent auditing firm. This engagement, disclosed in the Company’s 2024 Form 10-K, underscores BioRegenx’s ongoing commitment to transparency, accountability, and accurate financial reporting. BioRegenx continues to be advised by the New York-based law firm Sichenzia Ross Ference Carmel LLP. Partner Ross Carmel has supported the Company’s corporate uplisting strategy and introductions within its capital markets network. The Company values this relationship as part of its broader governance and advisory framework. Since completing its merger with Findit, In...